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CT modified radiotherapy planning in a significant percentage 
of patients. 
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Purpose or Objective: Ovarian cancer is a gynecological 
malignancy characterized by a dismal outcome for its 
tendency to metastasize despite aggressive systemic 
therapies, commonly carboplatin and paclitaxel. Among 
recurrent ovarian cancer, patients with oligometastatic 
disease are supposed to have a better prognosis since they 
could benefit from local approaches besides chemotherapy, 
considering also the limited alternative regimens of systemic 
therapy. The aim of our study is to evaluate the role of 
stereotactic body radiotherapy (SBRT) in terms of LC and 
toxicity in a setting of patients with oligometastatic 
recurrent ovarian cancer. 
 
Material and Methods: Between January 2011 and February 
2015, 15 patients (20 lesions) with recurrent oligometastatic 
ovarian carcinoma of any histology underwent SBRT. Toxicity 
and tumor response was scored using Radiation Therapy 
Oncology Group/European Organization for Research and 
Treatment of Cancer Scale. Tumor response was evaluated by 
CT/ PET, according to Response Evaluation Criteria in Solid 
Tumors. 
 
Results: Median age at treatment was 60 years and median 
follow-up was 21 months. The sites of disease were 
abdomino-pelvic lymphnodes (13 lesions), liver metastasis (4 
lesions), lung metastatasis (2 lesions) and para-vaginal mass 
(1 lesion). The SBRT doses were prescribed based on 
dimensions of target volumes and organs at risk constraints as 
follow: for lymphnodal lesions the dose prescription was 36-
45 Gy in 6 fractions and only one case treated with 40 Gy in 4 
fr; for hepatic lesions 61.89 -75 Gy in 3 fractions, for the 
pulmonary lesions both cases received 48 Gy in 4 fractions 
meanwhile in the para vaginal recurrence dose prescription 
was 36 Gy in 6 fractions. None of the patients had grade 3 /4 
acute or late Gu or Gi toxicity. At a median follow-up of 21 
months local control was observed in 85%. Complete 
radiologic response, partial response and progressive disease 
were observed in 12 (60%), 5 (25%) and respectively 3 cases 
(15%). 
 
Conclusion: SBRT is a feasible and well tolerated treatment 
approach in oligo-metastatic ovarian patients, offering a 
good local control. Certainly, additional patients and longer 
follow-up are necessary to confirm the impact of local 
treatment as SBRT in ovarian cancer therapy. 
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Purpose or Objective: This is a concern about hematological 
toxicity (HT) of intensity-modulated radiation therapy (IMRT) 
technique combined with chemotherapy used in the 
treatment of gynecological malignancies due to the high 
volume of low radiotherapy doses given to bone marrow. We 
aimed to determine if pelvic IMRT increased HT and which 
dosimetric parameters were predictors of this toxicity. 
 
Material and Methods: Ninety-nine consecutive cervical 
cancer patients treated with radio-chemotherapy (45-50,4Gy 
with Cisplatin 40mg/m2/week) between IX2011 and V2015 
were included. Fifty patients received three-dimensional 
conformal radiotherapy (3D-CRT) (4-6 fields) and 49 IMRT 
with RapidArc. Target volumes were contoured in accordance 
with RTOG Atlas guidelines. Pelvic bone marrow was defined 
using a computed tomography density-based autocontouring 
algorithm. HT was graded by Common Terminology Criteria 
for Adverse Events, version 4.0 criteria weekly during 
treatment. The rate of occurrence of grade III-IV HT (overall, 
anemia, thrombocytopenia, neutropenia, leucopenia) were 
evaluated in relation with radiotherapy technique, PTV, age, 
mean dose to bone marrow, volumes of bone marrow 
receiving 5, 10, 20, 30, and 40 Gy (V5, V10, V20, V30, and 
V40). The Chi2 test was used to compare HT for each studied 
parameter dichotomized at the median. Differences between 
IMRT and 3D-CRT technique were compared with U-Mann-
Whitney test. 
 
Results: Patients treated with IMRT had significantly lower 
V20, V30, V40, mean bone marrow dose, and PTV volume 
than 3D-CRT patients (p<.00001 for each). The both 
techniques did not differ significantly in age of patients, 
number of chemotherapy cycles given, V5 and V10. Grade III-
IV HT of any kind occurred in 52% of 3D-CRT patients and 30% 
of IMRT patients, p=0.03. Each evaluated threshold of dose 
given to bone marrow predicted significantly occurrence of 
HT. Larger PTV was not predictor of higher HT. 
 
Conclusion: Pelvic IMRT decreased HT of radio-chemotherapy 
for cervical cancer in comparison with 3D-CRT by reduction 
of volume of doses >20Gy given to bone marrow. Even though 
a precise dose threshold for bone marrow was not 
determined, limitation of bone marrow volume defined 
automatically as bone in patients treated with radio-
chemotherapy is warranted. 
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Purpose or Objective: Adjuvant intensity modulated 
radiotherapy (IMRT) for cervical cancer is associated with 
reduced late gastrointestinal toxicity (GI) however it’s impact 
on quality of life (QOL) is not known. The present matched 
pair analysis was performed to compare QOL between three-
dimensional conformal radiation (3DCRT) and IMRT. 
 
Material and Methods: From Jan,2011- Dec,2013 patients 
undergoing adjuvant or salvage radiation with 3DCRT or IMRT 
(with or without concurrent chemotherapy) and vaginal 
brachytherapy were included. Those who received systemic 
chemotherapy or extended field radiation were excluded. 
The study inclusion criteria also necessitated at least 1 year 
of follow up with QOL assessment at at least 2 time points. 
At follow up toxicity was documented using CTCAE version 
3.0 and QOL was measured with EORTC QLQC-30 and Cx-24 
module. The baseline characteristics of two cohorts were 
compared using chi-square test. Raw scores were converted 
into final scores using EORTC recommended conversion and 
linear mixed model was used to evaluate impact of time 
trends and treatment technique on QOL. A 10-point 
difference in QOL score and p≤0.05 was considered relevant 
and statistically significant. All data were analyzed using 
SPSS, version 20.0 and Graph pad Instat. 
 
Results: A total of 64 patients were eligible. Postoperative 
IMRT and 3DCRT was used in 40 and 24 patients respectively. 
The baseline socioeconomic, disease and treatment related 
characteristics were well balanced in both groups rendering 
cohorts eligible for a matched pair analysis. At one year 
there was recovery in most of the QOL domains in both 
cohorts with objective scores reaching baseline levels. The 
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recovery in QOL scores over time was deemed statistically 
significant (p<0.0001). A clinically and statistically significant 
improvement in physical (78.7 vs. 87.7, p=0.05), emotional 
(66.5 vs. 78.5, p=0.05) and social functioning (61.5 vs. 82.2) 
was observed in IMRT cohort. The patients treated with IMRT 
had fewer patients having symptoms of appetite loss (30.4 vs. 
12.1,p=0.01) and diarrhea (24 vs. 9;p=0.04). The use of IMRT 
was also associated with reduced lymphedema (15.2 vs 3.2; 
p=0.05). However no difference was observed in sexual and 
global QOL. 
 
Conclusion: Early results show improved functional scales 
and reduced symptom scales with use of postoperative IMRT 
when compared to 3DCRT. Further long term follow up is 
needed to clearly define the impact of IMRT on patient 
reported outcomes.  
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Purpose or Objective: Pelvic radiotherapy (RT) provides 
good local control in women with endometrial cancer (EC), 
but may also cause substantial acute and chronic adverse 
effects, which in turn may reduce patients' (pts) quality of 
life (QoL). 
 
Material and Methods: 293 pts who were treated with 
adjuvant pelvic RT for EC at our department between 2004 
and 2012 were asked to fill in questionnaires regarding their 
QoL (EORTC QLQ-C30, EN24). Median follow-up was 6 years. 
112 pts agreed to participate. 42 (38%) used the vaginal 
dilator (VD; group A) as prescribed, 62 (55%) did not use the 
VD (group B), 8 (7%) preferred not to answer this question. 
The values of the function and symptom scales of the pats 
were statistically analyzed and compared between the two 
groups as well as compared with reported values of normal 
populations. 
 
Results: The values of the function and symptom scales are 
generally lower in our pts compared to an age adapted 
normal population (NP). Pts reported statistically better 
values for sexual interest and sexual activity compared to NP 
(p<.0001), while sexual enjoyment was significantly reduced 
(p<.0001). Vaginal dryness and pain during intercourse 
(p<.00001) were the leading complaints. Sexual interest and 
activity increased with age (p<.0005) in contrast to NP. Pts in 
group A were younger than in group B (p=.016). Group A 
reported significantly less pain in the back and pelvis 
(p=.005) as well as less muscular pain (p=.013). Pts using VD 
>1 year had better values for sexual interest (p=.0022) and 
sexual activity (p=.013) compared to ≤ 1 year. Pts with 
vaginal brachytherapy (IVB) only had a better global health 
status compared to pts with additional external beam RT, 
while IMRT was better than 3D-conformal RT (p<.0017). Pts 
with higher acute GI toxicity reported more chronic GI 
symptoms (p=.002) with diarrhea (p=.009), nausea/vomiting 
(p=.032) as well as poorer social functioning (p=.036). Pts 
with higher acute GU toxicity reported more pain during 
intercourse (p=.044). 
 
Conclusion: Pelvic RT substantially affects QoL even years 
after treatment. Women participating in our study were more 
sexually active than the normal population. Therefore 
sexuality is important for QoL in women after endometrial 
cancer, even at higher age. The vaginal dilator is capable of 
improving chronic pelvic pain, sexual interest and sexual 
activity when used longer than one year. Pts with higher 
acute toxicities also exhibit more chronic problems. IMRT 
seems to be beneficial for long-term QoL. 
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Purpose or Objective: Uterine motion is a challenging issue 
in applying intensity-modulated radiotherapy (IMRT) for 
patients with cervical cancer. In this study we quantified the 
inter-fraction uterus movement during a course of definitive 
radiotherapy (RT) to determine the predictive factors 
affecting uterine motion. 
 
Material and Methods: A total of 343 cone-beam CT 
(CBCT）scans from 43 patients who underwent definitive RT 
were analyzed retrospectively. The median age of the 
patients was 58 years (range, 34-85 years). The FIGO stages 
were as follows: IB1, 9; IB2, 6; IIA, 1; IIB, 12; IIIB, 10; and 
IVA, 5. Cervical and corpus movement (mm) were measured 
for each direction (cranial [C), anterior [A), left [L) and right 
[R) for the uterine corpus; and A, posterior [P), L, and R for 
the cervix） by comparing planning CT and CBCT. The mean 
movement of each patient was analyzed according to the 
following factors: age; tumor stage; BMI; area of visceral fat 
in the umbilical plane, as assessed by CT; circumference of 
abdominal girth; history of abdominal surgery; uterine 
orientation (anteverted or retroverted); size of the uterus; 
tumor diameter; and tumor invasion to the corpus． 
 
Results: The mean movement of the corpus was as follows: 
C, 5.8 mm (range, 0-29.0 mm); A, 5.2 mm (range, 0.3-37.7 
mm); L, 2.4 mm (range, 0-10.6 mm); and R, 2.5 mm (range, 
0-9.2 mm). The mean movement of the cervix was as follows: 
A, 3.2 mm (range, 0-11.4 mm); P, 2.4 mm (range, 0-12.5 
mm); L, 1.5 mm (range, 0-9.2 mm); and R, 1.6 mm (range, 0-
7.3 mm). There was a significant correlation between 
abdominal girth and anterior movement of the corpus (r=-3.6 
and p=0.029). Tumor invasion to the corpus had a negative 
correlation with posterior movement of the cervix with 
marginal statistical significance (p=0.05)． 
 
Conclusion: The study demonstrated that abdominal girth 
and tumor invasion to the corpus were predictive factors of 
uterine motion during definitive RT for patients with cervical 
cancer． 
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Purpose or Objective: The aim of this study is to investigate 
the ADCmean of the primary tumor to evaluate their 
correlations with the recurrence and survival rates in patients 
with primary cervical cancer before and after definitive CRT. 
 
Material and Methods: The data of 44 patients with 
histologically proven squamous cell carcinoma of cervix was 
retrospectively evaluated .All patients had multi-parametric 
pelvic MR imaging (CE-MRI and DW-MRI) and 18F-FDG PET/CT 
for initial staging prior to treatment and also multi-
parametric pelvic MR imaging after treatment at our 
Institution between February 2009 and May 2014. ADC 
response was measured by the proportion of ADC changes 
between pretreatment and posttreatment ADC measured in 
DW-MRI. The patients were divided into groups based on the 
pretreatment and posttreatment ADCmean of the primary 
tumor cutoff values derived from the ROC curves. Disease-
